PD-1 inhibitors combined with chemotherapy for relapsed/refractory diffuse large B cell lymphoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025310

Enrollment

Unknown

Registered

2019-08-22

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapse or refractory diffuse large B cell lymphoma

Interventions

single arm:PD-1 inhibitors combined with chemotherapy

Eligibility

Sex/Gender

All

Age

15 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The patient or his/her legal guardians must sign a consent form; 2. The patient ages 15 years to 80 years, male or female; 3. By pathology,imagingcell,morphology and flow cytometry analysis examination diagnosis of patients with B-cell lymphoma. Diagnosed as poor curative effect after standard treatment scheme or refractory B-cell lymphoma; 4. The patient has lesions which can be measured or evaluated; 5. Main organs seem to be functioning well: Liver function: bilirubin = 95%; Heart function: LVEF >= 40%; 6. Peripheral venous blood in patients flow smoothly; 7. Karnofsky score >= 60.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients who want to be pregnant in 1 year; 3. Patients who can not use contraception in 1 year; 4. Uncontrolled active infection with in 4 weeks; 5. Active hepatitis B or hepatitis C virus infection; 6. HIV infected patients; 7. Patients with other cancers diagnosised by pathology; 8. Patients with serious autoimmune diseases or immunodeficiency; 9. Patients who suffer from allergies; 10. Patients who have taken part in other clinical tests within 6 weeks; 11. Patients who use systemic steroids before treatment within 4 weeks; 12. Patients who have a history of central nervous system disease; 13. Patients who are addicted to some drugs; 14. Patients who are not allowed to take part in the test(judged by the researchers).

Design outcomes

Primary

Measure	Time frame
Imaging methods (PET-CT, General diffusion MRI, or CT) would used to detect tumor progression and remission in patients with B-cell lymphoma;	—

Secondary

Measure	Time frame
PD-1 expression of T cells in peripheral blood;	—

Countries

China

Contacts

Public ContactDeng Qi

Tianjin First Central Hospital

kachydeng@hotmail.com+86 13612055872

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026